Resolution of nonalcoholic steatohepatits after gastric bypass surgery

作者: Xiuli Liu , Audrey J. Lazenby , Ronald H. Clements , Nirag Jhala , Gary A. Abrams

DOI: 10.1007/S11695-007-9086-2

关键词:

摘要: Background: Nonalcoholic fatty liver disease (NAFLD) has been increasingly recognized as a common chronic condition. Previous studies have variable regarding the histological outcomes after rapid weight loss. The aim of this study was to characterize histopathologic changes in NASH following laparoscopic Roux-en-Y Gastric Bypass surgery (LRYGBP). Methods: We retrospectively analyzed paired needle biopsies taken during and LRYGBP 39 patients according recent NIH-based NAFLD criteria. Results: cohort included 33 females 6 males (range 24-57 years). 23 (58.9%) had steatohepatitis, 12 with (30.7%), 4 were normal (10.2%). Follow-up performed at mean interval 18 months 6-41 months). No significant differences length or number portal tracts between noted. decrease BMI 50.2 kg 18.2 kg/m 2 , respectively. initial prevalence hepatic pathology: steatosis (89.7%), hepatocellular ballooning (58.9%), centrilobular/perisinusoidal fibrosis (50%) improved significantly LRYGBP: (2.9%), (0%), centrilobular (25%). Mitigation lobular inflammation score (2.23±0.63 vs 1.95±0.56, P=0.01) stage (1.14±1.05 0.72±0.97, P=0.002) also However, no improvements detected tract fibrosis. Conclusions: Over period months, resolution occurs LRYGBP. Long-term are warranted assess for potential regions relapse that could result regain malnutrition.

参考文章(30)
Shivakumar Chitturi, Geoffrey C. Farrell, Etiopathogenesis of Nonalcoholic Steatohepatitis Seminars in Liver Disease. ,vol. 21, pp. 027- 042 ,(2001) , 10.1055/S-2001-12927
Samuel Klein, Bettina Mittendorfer, J. Christopher Eagon, Bruce Patterson, LaFaine Grant, Nikki Feirt, Ekihiro Seki, David Brenner, Kevin Korenblat, Jennifer McCrea, Gastric Bypass Surgery Improves Metabolic and Hepatic Abnormalities Associated With Nonalcoholic Fatty Liver Disease Gastroenterology. ,vol. 130, pp. 1564- 1572 ,(2006) , 10.1053/J.GASTRO.2006.01.042
Kevin B. Barker, Nicole A. Palekar, Steven P. Bowers, Joel E. Goldberg, Joseph P. Pulcini, Stephen A. Harrison, Non-Alcoholic Steatohepatitis: Effect of Roux-en-Y Gastric Bypass Surgery The American Journal of Gastroenterology. ,vol. 101, pp. 368- 373 ,(2006) , 10.1111/J.1572-0241.2006.00419.X
Gary A. Abrams, Sachin S. Kunde, Audrey J. Lazenby, Ronald H. Clements, Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease. Hepatology. ,vol. 40, pp. 475- 483 ,(2004) , 10.1002/HEP.20323
Attila Csendes, Gladys Smok, Ana Burgos, Histological findings in the liver before and after gastric bypass. Obesity Surgery. ,vol. 16, pp. 607- 611 ,(2006) , 10.1381/096089206776944904
Charalabos Stratopoulos, Alexandros Papakonstantinou, Ioannis Terzis, Charis Spiliadi, George Dimitriades, Vasiliki Komesidou, Panagiota Kitsanta, Theodoros Argyrakos, Evagelos Hadjiyannakis, Changes in Liver Histology Accompanying Massive Weight Loss after Gastroplasty for Morbid Obesity Obesity Surgery. ,vol. 15, pp. 1154- 1160 ,(2005) , 10.1381/0960892055002239
Paul E O’Brien, John B Dixon, The extent of the problem of obesity. American Journal of Surgery. ,vol. 184, pp. 4- 8 ,(2002) , 10.1016/S0002-9610(02)01172-8
Arun J. Sanyal, Pouneh S. Mofrad, Melissa J. Contos, Carol Sargeant, Velimir A. Luketic, Richard K. Sterling, R. Todd Stravitz, Mitchell L. Shiffman, John Clore, Alan S. Mills, A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis Clinical Gastroenterology and Hepatology. ,vol. 2, pp. 1107- 1115 ,(2004) , 10.1016/S1542-3565(04)00457-4
Michael Korenkov, Stefan Sauerland, Theodor Junginger, Surgery for obesity. Current Opinion in Gastroenterology. ,vol. 21, pp. 111- 115 ,(2006) , 10.1097/01.MOG.0000182859.04046.0E
Brent A. Neuschwander-Tetri, Elizabeth M. Brunt, Kent R. Wehmeier, Dana Oliver, Bruce R. Bacon, Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone Hepatology. ,vol. 38, pp. 1008- 1017 ,(2003) , 10.1002/HEP.1840380427